Certuity LLC lifted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 28.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,168 shares of the exchange traded fund’s stock after purchasing an additional 2,494 shares during the period. Certuity LLC’s holdings in SPDR S&P Biotech ETF were worth $1,006,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of SPDR S&P Biotech ETF by 198.6% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock valued at $911,825,000 after purchasing an additional 6,138,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new position in SPDR S&P Biotech ETF in the third quarter valued at approximately $141,284,000. Assetmark Inc. lifted its holdings in SPDR S&P Biotech ETF by 72,653.0% in the third quarter. Assetmark Inc. now owns 589,299 shares of the exchange traded fund’s stock valued at $58,223,000 after acquiring an additional 588,489 shares during the last quarter. Sivik Global Healthcare LLC acquired a new position in SPDR S&P Biotech ETF in the third quarter valued at approximately $29,640,000. Finally, Mirae Asset Securities USA Inc. lifted its holdings in SPDR S&P Biotech ETF by 50.0% in the third quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after acquiring an additional 300,000 shares during the last quarter.
SPDR S&P Biotech ETF Stock Performance
XBI opened at $89.05 on Wednesday. The business’s 50 day moving average price is $92.23 and its 200 day moving average price is $96.30. SPDR S&P Biotech ETF has a one year low of $81.14 and a one year high of $105.47. The stock has a market capitalization of $6.79 billion, a PE ratio of 11.47 and a beta of 1.11.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Breakout Stocks: What They Are and How to Identify Them
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Stock Dividend Cuts Happen Are You Ready?
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Roth IRA Calculator: Calculate Your Potential Returns
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.